GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Purchase Of Investment

IPHYF (Innate Pharma) Purchase Of Investment : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Purchase Of Investment?

Innate Pharma's purchase of investment for the six months ended in Jun. 2024 was $0.00 Mil. It means Innate Pharma spent $0.00 Mil on purchasing investments. Innate Pharma's purchase of investment for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2023 ), Innate Pharma spent the same money on purchasing investments in Jun. 2024 ($0.00 Mil).

Innate Pharma Purchase Of Investment Historical Data

The historical data trend for Innate Pharma's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Purchase Of Investment Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -3.65 - - -

Innate Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Innate Pharma Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innate Pharma Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (OTCPK:IPHYF) » Definitions » Purchase Of Investment
Comparable Companies
XPAR:OSE XPAR:GNFT XPAR:ALCLS XPAR:NANO XPAR:ALSEN XPAR:IVA XPAR:MAAT XPAR:TNG XPAR:ADOC XPAR:DBV VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IPHA:USA 0EVI:UK IPH:France IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.